Compare GUG & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GUG | CRVS |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 634.0M |
| IPO Year | N/A | 2016 |
| Metric | GUG | CRVS |
|---|---|---|
| Price | $15.50 | $7.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | 108.9K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 9.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.71 | $2.54 |
| 52 Week High | $15.06 | $9.60 |
| Indicator | GUG | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 38.18 |
| Support Level | $15.27 | $8.31 |
| Resistance Level | $15.53 | $9.60 |
| Average True Range (ATR) | 0.24 | 0.57 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 62.01 | 6.81 |
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).